2026-04-27
ABOUT
HISKY
HISKY
About HISKY
Hisky Medical, a leading innovative medical technology company originated from Tsinghua University, takes "Popularize high-end technology, Protect public health" as core mission and committed to making outstanding contributions to healthcare business. Hisky owns multiple independent research and development brands, including iLivTouch® Non-invasive Liver Disease Management System, CelTouch Confocal Microprobe lmaging Device, EQTouch High-end Ultrasound Platform,Breast Disease diagnosis & treatment solutions and so on. The product solutions cover non-invasive screening, diagnosis and post-diagnosis management in liver, digestion, endocrine, physical examination, respiratory, breast, urology, surgery and other fields.
Learn More
R&D Center(Jiangsu、Beijing)
2
Global Manufacturing Center
20000 m²
About HISKY
Hisky Medical, a leading innovative medical technology company originated from Tsinghua University, takes "Popularize high-end technology, Protect public health" as core mission and committed to making outstanding contributions to healthcare business. Hisky owns multiple independent research and development brands, including iLivTouch® Non-invasive Liver Disease Management System, CelTouch Confocal Microprobe lmaging Device, EQTouch High-end Ultrasound Platform,Breast Disease diagnosis & treatment solutions and so on. The product solutions cover non-invasive screening, diagnosis and post-diagnosis management in liver, digestion, endocrine, physical examination, respiratory, breast, urology, surgery and other fields.
Learn More
Patents applied globally
600 +
Units installed worldwide
5000 +
iLivTouch®Non-invasive Liver Disease Management System
CelTouch Confocal Microprobe lmaging System
EQTouch High-end Ultrasound Platform
RECENT NEWS
News Center
Learn More
2026-04-19
Led by Xinwei Hao and Ningli Chai, the research enrolled 29 PCL patients who underwent concurrent EUS-guided fine-needle aspiration (EUS-FNA) and nCLE. The core goal was to evaluate nCLE’s ability to distinguish concomitant ablation-eligible lesions (CAELs) from ablation-ineligible lesions (CAILs) intraoperatively, and compare its diagnostic performance to traditional EUS morphology and cyst fluid string sign assessments
2026-02-10
2026-01-15
2026-01-01
2025-11-14